HIV
Conditions
Brief summary
HVTN 144 is a phase 1 clinical trial to being conducted to evaluate the safety and immunogenicity of an HIV envelope trimer, N332-GT5 gp140, adjuvanted with saponin/MPLA nanoparticles (SMNP) in adult participants without HIV. The study aims to evaluate the safety and tolerability of N332-GT5 gp140 adjuvanted with SMNP in adult volunteers without HIV and in overall good health, including identifying a safe and tolerable dose, route, and schedule of administration of the novel adjuvant SMNP. The study also aims to evaluate the induction of BG18-class immunoglobulin G (IgG) B-cell responses in memory B cells by the study regimens and compare the responses between the different groups. HVTN 144 will be conducted in 2 parts with 84 volunteers without HIV and in overall good health, aged 18 to 55 years. The study duration is 22 months which includes 8 months for enrollment, planned safety holds, follow-up, and Adverse Event of Special Interest (AESI) health contact 1 year after last vaccination.
Detailed description
This study will evaluate the safety and immunogenicity of combining 2 FIH products: N332-GT5 gp140 HIV trimer protein adjuvanted with SMNP, co-administered as 2 bolus immunizations (week 0 and 8) or fractionated escalating dose prime (6 immunizations over 3 weeks) followed by bolus immunization boost (week 10), via either subcutaneous (SC) route in the upper arm or intramuscular (IM) route to the deltoid. N332-GT5 gp140 is based on the BG505 MD39 native-like trimer (NLT). The dose escalation study (Part A) will determine the maximum safe dose, within our schema, of N332-GT5 gp140 and SMNP for 4 vaccination modalities: IM/bolus, IM/fractionated escalating dose prime, SC/bolus, and SC/fractionated escalating dose prime. A primary endpoint will be safety and tolerability. The trial will evaluate: (1) the concept of generalized germline targeting for HCDR3-dominant bnAb precursors; (2) germline targeting for V3-glycan (V3G)-specific BG18-class bnAbs; (3) establishing a safe and effective dose of SMNP in humans; (4) immunogenicity of an HIV Env trimer adjuvanted with SMNP; and (5) ranking of HIV trimer immune response magnitude and quality for bolus/IM, bolus/SC, and fractionated escalating dose with one of either IM or SC.
Interventions
BIOLOGICALN332-GT5 gp140 (IM, Bolus)
IM in the deltoid
BIOLOGICALN332-GT5 gp140 (IM, Fractioned)
IM in the deltoid, Fractionated escalating dose for prime
BIOLOGICALN332-GT5 gp140 (SC, Bolus)
SC in the upper arm
BIOLOGICALN332-GT5 gp140 (SC, Fractioned)
SC in the upper arm, Fractionated escalating dose for prime
BIOLOGICALSMNP (IM, Bolus)
IM in the deltoid
BIOLOGICALSMNP (IM, Fractioned)
IM in the deltoid, Fractionated escalating dose for prime
BIOLOGICALSMNP (SC, Bolus)
SC in the upper arm
BIOLOGICALSMNP (SC, Fractioned)
SC in the upper arm, Fractionated escalating dose for prime
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Department of Health and Human Services
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
The overall design of this trial involves 2 parts. In Part A, the goal is to establish the tolerability of both N332-GT5 and the SMNP adjuvant. This is a partially randomized design - Part A is nonrandomized, and Part B is randomized.
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
General and demographic criteria: 1. Age of 18 through 55 years 2. Access to a participating HVTN Clinical Research Site (CRS) and willingness to be followed for the planned duration of the study 3. Ability and willingness to provide informed consent 4. Assessment of Understanding (AoU): Volunteer demonstrates understanding of this study by completing a questionnaire prior to the first vaccination with verbal demonstration of understanding of all questionnaire items answered incorrectly 5. Agrees not to enroll in another study of an investigational research agent until completion of the study 6. Good general health as shown by medical history, physical exam, and screening laboratory tests HIV-related criteria: 7. Willingness to receive HIV test results 8. Willingness to discuss HIV risks and amenable to HIV risk-reduction counseling 9. Assessed by the clinic staff as having a low likelihood of acquiring HIV and is committed to avoiding behaviors associated with a higher likelihood of acquiring HIV through the last required protocol clinic visit Laboratory inclusion values Criteria: 10. Hemoglobin (Hgb) * ≥ 11.0 g/dL for volunteers who were assigned female sex at birth (AFAB) * ≥ 13.0 g/dL for volunteers who were assigned male sex at birth (AMAB) and transgender men who have been on hormone therapy for more than 6 consecutive months * ≥ 12.0 g/dL for transgender women who have been on hormone therapy for more than 6 consecutive months * For transgender volunteers who have been on hormone therapy for less than 6 consecutive months, determine Hgb eligibility based on their sex assigned at birth 11. White blood cell (WBC) count = 2500 to 12000 cells/mm3 with normal differential, or differential approved by Investigator of Record (IoR) as not clinically significant 12. Total lymphocyte count ≥ 650 cells/mm3 with normal differential, or differential approved by IoR as not clinically significant 13. Remaining differential either within local lab reference range or with site physician approval 14. Platelets = 125000 to 550000 cells/mm3 15. Chemistry panel: Alanine aminotransferase (ALT) \< 1.25 times the institutional upper limit of normal (ULN); serum creatinine ≤ 1.1 x ULN based on the local lab reference range. 16. Corrected total serum calcium level of ≥ 8.5 mg/dL 17. Negative HIV-1 and -2 blood test: US volunteers must have a negative FDA-approved enzyme immunoassay (EIA) or chemiluminescent microparticle immunoassay (CMIA) 18. Negative Hepatitis B surface antigen (HBsAg) 19. Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV nucleic acid test (NAT) if the anti-HCV is positive. Reproductive status criteria: 20. For volunteers AFAB or intersex at birth and are capable of becoming pregnant (hereafter referred to as "persons of pregnancy potential"): * Must agree to use effective means of contraception for sexual activity that could lead to pregnancy from at least 21 days prior to enrollment and 4 weeks after their last scheduled vaccination timepoint. * Must have a negative beta human chorionic gonadotropin (β-HCG) pregnancy test (urine or serum) at screening (ie, prior to randomization, if applicable) and prior to study-product administration on the day of study-product administration. (Persons of pregnancy potential require a pregnancy test prior to injection 1 of the fractionated escalating dose series) * Persons who are NOT of pregnancy potential due to having undergone hysterectomy or bilateral oophorectomy (verified by medical records) or having reached menopause (no menses for 1 year) are not required to undergo pregnancy testing. 21. AFAB volunteers or volunteers who were intersex at birth must also agree not to seek pregnancy through alternative methods, such as oocyte retrieval, artificial insemination or in vitro fertilization until after the last required protocol clinic visit.
Exclusion criteria
General criteria: 1. Blood products received within 120 days before first vaccination 2. Investigational research agents received within 30 days before first vaccination 3. Body mass index (BMI) ≥ 40, or BMI ≥ 35 with 2 or more of the following: Age \> 45, systolic blood pressure \> 140 mm Hg, diastolic blood pressure \> 90 mm Hg, current smoker, known hyperlipidemia 4. Intent to participate in any other study that requires non-HVTN HIV Ab testing during the planned duration of the HVTN 144 study 5. Pregnant or breastfeeding 6. Active duty and reserve US military personnel Vaccines and other injections criteria: 7. HIV vaccine(s) received in a prior HIV vaccine trial. For volunteers who have received control/placebo in an HIV vaccine trial, the HVTN 144 Protocol Safety Review Team (PSRT) will determine eligibility on a case-by-case basis. 8. Previous receipt of monoclonal antibodies (mAbs), whether licensed or investigational. Exceptions may be made by the HVTN 144 PSRT on a case-by-case basis. 9. Non-HIV experimental vaccine(s) received within the last 1 year in a prior vaccine trial. Exceptions may be made by the HVTN 144 PSRT for vaccines that have subsequently undergone licensure by the FDA. For volunteers who have received control/placebo in an experimental vaccine trial, the HVTN 144 PSRT will determine eligibility on a case-by-case basis. For volunteers who have received an experimental vaccine(s) more than 1 year ago, eligibility for enrollment will be determined by the HVTN 144 PSRT on a case-by-case basis. 10. Live attenuated vaccines received within 30 days before the first vaccination or scheduled within 28 days after injection (eg, measles, mumps, and rubella (MMR); oral polio vaccine (OPV); varicella; yellow fever; live attenuated influenza vaccine). ACAM2000 vaccine \>28 days prior with a vaccination scab still present. 11. Any vaccines that are not live attenuated vaccines and were received within 14 days prior to the first vaccination (eg, tetanus, pneumococcal, Hepatitis A or B). Please note this includes incompetent vaccine such as the Jynneos vaccine for the prevention of mpox disease. 12. Allergy treatment with antigen injections within 30 days before the first vaccination or that are scheduled within 14 days after the first vaccination Immune system criteria: 13. Immunosuppressive medications received within 168 days before first vaccination (not exclusionary: \[1\] corticosteroid nasal spray; \[2\] inhaled corticosteroids; \[3\] topical corticosteroids for mild, uncomplicated dermatologic condition; or \[4\] a single course of oral/parenteral prednisone or equivalent at doses \< 60 mg/day and length of therapy \< 11 days with completion at least 30 days prior to enrollment) 14. Serious adverse reactions to vaccines or to vaccine components such as AS01B ("Shingrix") or Matrix M (Novovax CoV2373), including history of anaphylaxis and related symptoms, such as hives, respiratory difficulty, angioedema, and/or abdominal pain (not exclusionary: a volunteer who had a nonanaphylactic adverse reaction to pertussis vaccine as a child). 15. IgG received within 60 days before first vaccination (for mAbs, see criterion #8 above) 16. Autoimmune disease, current or history (not exclusionary: mild, well-controlled psoriasis) 17. AESIs: Volunteers who currently have, or have a history of, any condition that could be considered an AESI for the product(s) administered in this protocol. 18. Immunodeficiency Clinically significant medical conditions criteria: 19. Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to: * A process that would affect the immune response, * A process that would require medication that affects the immune response, * Any contraindication to repeated injections or blood draws, * A condition that requires active medical intervention or monitoring to avert grave danger to the volunteer's health or well-being during the study period, * A condition or process for which signs or symptoms could be confused with reactions to vaccine, or * Any condition specifically listed among the
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local reactogenicity signs and symptoms (solicited adverse events) will be collected | Through study completion, an average of 1 year |
| Systemic reactogenicity signs and symptoms (solicited adverse events) will be collected | Through study completion, an average of 1 year |
| Number of Serious Adverse Events (SAEs) leading to early participant withdrawal or permanent discontinuation | 35 weeks and for 12 months following any receipt of study product |
| Number of Medically attended adverse events (MAAEs) leading to early participant withdrawal or permanent discontinuation | 35 weeks and for 12 months following any receipt of study product |
| Number of AESIs leading to early participant withdrawal or permanent discontinuation | 35 weeks and for 12 months following any receipt of study product |
| Number of Adverse Events (AEs) leading to early participant withdrawal or permanent discontinuation | 35 weeks and for 12 months following any receipt of study product |
| Comparison of number of reported/assessed local and systemic reactogenicity, SAE's and AESI's and medically attended adverse events at increasing doses of adjuvant at constant dose of N332-GT5 gp140 | 35 weeks |
| Frequency of BG18 epitope-specific B cells as determined by flow cytometry | 35 weeks |
| Proportion of participants with BG18-class IgG memory B cells in peripheral blood mononuclear cell (PBMCs), measured by antigen-specific B-cell sorting, B-cell receptor (BCR) sequencing, and bioinformatic analysis | 35 weeks |
| Frequency of BG18-class B cells among IgG memory B cells in PBMCs, measured by antigen-specific B-cell sorting, BCR sequencing, and bioinformatic analysis | 35 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of participants with BG18-class IgG B cells, measured by antigen-specific B-cell sorting, BCR sequencing, and bioinformatic analysis | 35 weeks |
| Frequency of BG18-class B cells among IgG B cells in germinal centers (GCs), measured by antigen-specific B-cell sorting, BCR sequencing, and bioinformatic analysis | 35 weeks |
| Response rate of serum binding Ab responses to N332-GT5 gp140 and BG18 epitope on the trimer measured by binding antibody multiplex assay (BAMA) | 35 weeks |
| Magnitude of serum binding Ab responses to N332-GT5 gp140 and BG18 epitope on the trimer measured by binding antibody multiplex assay (BAMA) | 35 weeks |
| Response rate of serum neutralizing antibodies (nAbs) that neutralize pseudoviruses engineered to be sensitive to BG18-precursors | 35 weeks |
| Concentration of serum nAbs that neutralize pseudoviruses engineered to be sensitive to BG18-precursors | 35 weeks |
| Frequency of N332-GT5 gp140 trimer-specific B cells | 35 weeks |
| Frequency of BG18 sequences isolated postvaccination | 35 weeks |
| Magnitude of binding Abs measured by BAMA | 35 weeks |
Countries
United States
Contacts
STUDY_CHAIRLindsey Baden
Brigham and Women's Hospital
Outcome results
None listed